Curative Effect of Aprepitant Preventing CINV

• Published in: Zhongguo fei ai za zhi 2018-10, Vol.21 (10), p.800-804
• Main Authors: Guan, Shasha, Zhang, Lisha, Zhong, Diansheng, Ma, Qing, Meng, Fanlu, Shao, Yi, Yu, Tao, Liu, Xia
• Format: Article
• Language: Chinese
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Aprepitant; Cancer; Chemotherapy; CINV; Cisplatin; Cisplatin - adverse effects; Female; Humans; Male; Middle Aged; Morpholines - pharmacology; Mortality; Nausea; Nausea - chemically induced; Nausea - prevention & control; Prevention; Quality of Life; Vomiting; Vomiting - chemically induced; Vomiting - prevention & control
• ISSN: 1009-3419; 1999-6187; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2018.10.12

Chemotherapy is the most important method for cancer treatment. However, chemotherapy induced nausea and vomiting (CINV) has a profound effect on patients. In recent years, there have been new antiemetic drugs, such as aprepitant. We review the curative effect of aprepitant with tropisetron and dexamethasone for prevention of nausea and vomiting in patients receiving Cisplatin chemotherapy. Observation is divided into three stages. Whole study phase (0-120 h after chemotherapy administration), acute phases (0-24 h), and delayed phase (24 h-120 h). The primary endpoints were complete response (CR) and complete prevention (CP) during the three different study phase. In the whole study phase, 86.02% of patients achieved CR; in acute phases and delayed phases were 89.25%, 87.1%, respectively. CP were 46.22%, 83.87%, 45.16%, respectively. Anti-CINV effect was significantly associated with age distribution (P=0.008). Aprepitant with tropisetron and dexamethasone prevented effectively CNIV for patients receiving Cis